Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 13/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14524004 | 0.84 | PIN1 (0.46) | PIN1MAPTHTTMEN1CYP1A2 | |
| SCHEMBL4191609 | 0.83 | PIN1 (0.53) | PIN1MAPTHTTL3MBTL1PGK1 | |
| SCHEMBL26842941 | 0.81 | PIN1 (0.44) | PIN1MAPTHTTL3MBTL1 | |
| SCHEMBL17769548 | 0.80 | PIN1 (0.45) | PIN1MAPTHTT | |
| SCHEMBL17769547 | 0.80 | PIN1 (0.45) | PIN1MAPTHTT | |
| SCHEMBL26634260 | 0.80 | MAPT (0.53) | PIN1MAPTHTTMEN1CYP1A2 | |
| SCHEMBL1496408 | 0.78 | PIN1 (0.57) | PIN1MAPTHTTL3MBTL1GLP1R | |
| SCHEMBL4580244 | 0.78 | PIN1 (0.51) | PIN1MAPTHTTL3MBTL1GLP1R | |
| SCHEMBL4580251 | 0.78 | PIN1 (0.51) | PIN1MAPTHTTL3MBTL1GLP1R | |
| SCHEMBL30634583 | 0.78 | KMT2A (0.51) | PIN1MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745454-B2 | Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080182850-A1 | 3-(HETEROARYL)ALANINE DERIVATIVES-INHIBITORS OF LEUKOCYTE ADHESION MEDIATED BY VLA-4 | WYETH | 2008-07-31 | — | — | US | disclosed |
| US-7365073-B2 | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182850-A1 | 3-(HETEROARYL)ALANINE DERIVATIVES-INHIBITORS OF LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, AADAT, ICAM1 | PIN1 2806/4885MAPT 1254/4885HTT 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.